Since HC-5404 showed acceptable tolerability and safety profile in the clinical setting with advanced solid tumors [244], it could be interesting to test whether combining HC-5404 with anti-PD-1 therapy or VEGF receptor tyrosine kinase inhibitors might be effective in cancer patients who are unresponsive or resistant to these treatments. Here, PDCD1 is linked to cancer.